Doxazosin
Product Images NDC 67544-273

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 67544-273). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 8mg (67544 273)

Label for Doxazosin Mesylate 8 mg tablets, containing 45 tablets per container. The label indicates the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC, with original manufacturing by Mylan Pharmaceuticals Inc. It includes storage instructions and specifies the product is for prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (A7293678 9b1b 4102 9a79 1000d853dc16 01)

Chemical structure of doxazosin mesylate, showing its molecular composition including methoxy groups, piperazine ring, and naphthalene moiety associated with the mesylate salt.*

FDA Label Image

Figure 1 (A7293678 9b1b 4102 9a79 1000d853dc16 02)

Figure 1 from Study 1 presents two line graphs comparing Doxazosin and placebo over 14 weeks. The left graph shows the mean change in total symptom score from baseline, with Doxazosin showing a greater decrease. The right graph depicts the mean increase in maximum urinary flow rate from baseline, where Doxazosin shows a greater increase than placebo over the treatment duration.*

FDA Label Image

Table 1 (A7293678 9b1b 4102 9a79 1000d853dc16 03)

A data table and accompanying bar graph showing the effects of Doxazosin on symptom score and maximum flow rate across three clinical studies. The table includes baseline and mean change values for placebo and Doxazosin groups at various dosages and time points, with statistical significance noted. The bar graph illustrates maximum flow rate changes in Study 2 comparing placebo, 4 mg, and 8 mg doses of Doxazosin, highlighting significant differences.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.